Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04838275 · ClinicalTrials.gov registry record · NA
IPF mHealth Exercise Study
A NA study of Idiopathic Pulmonary Fibrosis, sponsored by University of Washington.
- Completed
- Registry status
- NA
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT04838275: Completed NA study of Idiopathic Pulmonary Fibrosis, sponsored by University of Washington.
NCT04838275 is a NA study of Idiopathic Pulmonary Fibrosis that has completed, run by University of Washington. The registered enrollment target is 32 participants, below the 751-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04838275, a NA study of Idiopathic Pulmonary Fibrosis, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- NA
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients with idiopathic pulmonary fibrosis (IPF) who are stable on antifibrotic therapy at least 3 months will be randomized to complete a 12-week home exercise intervention using an mHealth platform, plus a pre- and post-intervention monitoring period (4 weeks each) and in-person study assessments.
Primary Outcome
Daily activity as step counts, intensity (metabolic equivalents), and duration (METS\*min) of activity to identify number of minutes spent in moderate-to-vigorous physical activity (MVPA) vs. sedentary time
Conditions Studied
Interventions
- BEHAVIORAL 12-week mHealth home exercise prescription
Study Locations (1)
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2021-05-01 |
| Est. Completion | 2024-12-31 |
| Phase | NA |
What the finished NCT04838275 record still lists
NCT04838275 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 751-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Idiopathic Pulmonary Fibrosis appearing as the primary indexed condition, and to 1 intervention - of which 12-week mHealth home exercise prescription is the first listed.
NCT04838275 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT04838275 about?
NCT04838275 is a clinical study titled "IPF mHealth Exercise Study". Patients with idiopathic pulmonary fibrosis (IPF) who are stable on antifibrotic therapy at least 3 months will be randomized to complete a 12-week home exercise intervention using an mHealth platform, plus a pre- and post-intervention monitoring period (4 weeks each) and in-person study assessments...
What is the current status of trial NCT04838275?
This trial is currently completed. It is a NA study. The enrollment target is 32 participants. The study started on 2021-05-01. Estimated completion is 2024-12-31.
What conditions does trial NCT04838275 study?
This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis.
What interventions are being tested in trial NCT04838275?
The interventions under investigation include: 12-week mHealth home exercise prescription (BEHAVIORAL).
Who is sponsoring clinical trial NCT04838275?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04838275 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Pulmonary Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04838275's enrollment target sits among peer trials
32 39th of 51 higher than 12 of 51 other Idiopathic Pulmonary Fibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Idiopathic Pulmonary Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Yoga Effect on Quality of Life Study Among Patients with Idiopathic Pulmonary Fibrosis
ACTIVE NOT RECRUITING · NA
-
Palliative Care Planner (PCplanner)
COMPLETED · NA
-
A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
Hyperpolarized Xenon-129 MRI in Idiopathic Pulmonary Fibrosis
RECRUITING · Early Phase 1
-
Pulmonary Fibrosis Foundation Community Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI